MedTrace Logo

Early Administration of Recombinant Erythropoietin (RHEPO) in Transfusion Savings in Trauma Patients

NCT03867071 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2019-03-07

No results posted yet for this study

Summary

The objective of our study is to demonstrate the interest of early administration of recombinant erythropoietin in trauma patients

Conditions

Interventions

OTHER

recombinant erythropoietin injection

Intravenous injection of 300 international units (IU) per kg (kg) of recombinant erythropoietin with a maximum of 20.000 IU, daily for a maximum of 10 days (D0 to D9).

OTHER

placebo injection

Intravenous injection 0,9% saline solution.

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Nīmes

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03867071 on ClinicalTrials.gov